<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113789</url>
  </required_header>
  <id_info>
    <org_study_id>20030122</org_study_id>
    <nct_id>NCT00113789</nct_id>
  </id_info>
  <brief_title>Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer</brief_title>
  <official_title>Randomized, Phase 2 Study of Pegfilgrastim Given on the Last Day of a Multi-Day Topotecan Regimen or the Day After in Subjects With Relapsed or Refractory Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This trial will provide data on the safety and efficacy of pegfilgrastim, in terms of&#xD;
      duration of grade 4 neutropenia, when administered on the last day or the day after a&#xD;
      multi-day, myelosuppressive chemotherapy regimen for ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Grade 4 Neutropenia</measure>
    <time_frame>During treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Pegfilgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PI Discretion</intervention_name>
    <description>PI Discretion</description>
    <arm_group_label>Pegfilgrastim</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects with histologically confirmed primary peritoneal carcinoma,&#xD;
        epithelial ovarian cancer, or tubal carcinoma relapsed after or refractory to 1 or 2 prior&#xD;
        regimens of therapy - Measurable or evaluable disease - GOG Performance Status of 0 to 2 -&#xD;
        Subjects must be at least 2 weeks from major surgery and recovered from all associated&#xD;
        toxicities or sequelae - At least 2 weeks from radiation therapy and recovered from all&#xD;
        associated toxicities - Adequate hemopoietic function evidenced by: *ANC greater than 1.5 x&#xD;
        10^9/L, *platelets greater than 100 x 10^9/L and *hemoglobin greater than or equal to 10&#xD;
        g/dL - AST and ALT less than 1.5 x ULN; total serum bilirubin less than or equal to 2.0&#xD;
        mg/dL; serum creatinine less than or equal to 1.5 mg/dL or calculated creatinine clearance&#xD;
        greater than or equal to 60 mL/min Exclusion Criteria: - Epithelial ovarian tumors of low&#xD;
        malignant potential - Prior therapy with topotecan - Active infection requiring treatment&#xD;
        with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral&#xD;
        agent) within 72 hours of chemotherapy - Prior malignancy within the last 5 years, with the&#xD;
        exception of surgically cured basal/squamous skin cell carcinoma, and/or carcinoma of the&#xD;
        cervix in-situ - History of impaired cardiac status (e.g., severe heart disease,&#xD;
        cardiomyopathy, or congestive heart failure) - Any premalignant myeloid condition or any&#xD;
        malignancy with myeloid characteristics (e.g., myelodysplastic syndromes, acute or chronic&#xD;
        myelogenous leukemia - Subject is pregnant (e.g., positive HCG test) or breast feeding -&#xD;
        Subject is of child-bearing potential and does not agree to using adequate contraceptive&#xD;
        precautions - Any psychiatric, addictive or other kind of disorder which compromises the&#xD;
        ability of the subject to give written informed consent and/or to comply with study&#xD;
        protocol procedures - Other investigational procedures are excluded. Subject is currently&#xD;
        enrolled in, or has not yet completed at least 30 days since ending another investigational&#xD;
        device or drug trial(s) or is receiving other investigational agent(s)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf</url>
    <description>Notice regarding posted summaries of trial results</description>
  </link>
  <link>
    <url>http://download.veritasmedicine.com/REGFILES/amgen/08D_FDAMA_113_Posting_Summary_11_GCSFSD01_20030122.pdf</url>
    <description>To access clinical trial results information click on this link</description>
  </link>
  <link>
    <url>http://www.neulasta.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>June 10, 2005</study_first_submitted>
  <study_first_submitted_qc>June 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2005</study_first_posted>
  <last_update_submitted>February 12, 2009</last_update_submitted>
  <last_update_submitted_qc>February 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>topotecan</keyword>
  <keyword>neutropenia</keyword>
  <keyword>NeulastaÂ®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

